Displaying 1 - 1 of 1
| Active Ingredient | CEFUROXIME |
| Therapeutic Class | SECOND GEN CEPHALOSPORINS |
| Indications | Infections caused by susceptible Gram-positive and Gram-negative bacteria, including infections of the bones and joints, CNS, skin and skin structures, respiratory tract, genito-urinary tract (includi More ... |
| Caution | Gastrointestinal disturbances, including diarrhoea, nausea, and vomiting. Mild to moderate hearing loss has been reported in some children given cefuroxime for the treatment of meningitis. |
| Dose Range | Adult and children 12 years and over: 250 mg twice daily dose may be doubled in severe lower respiratory tract infections or if pneumonia is suspected; Pediatric: 3 months–2 years; 10 mg/kg twice daily (max. p er dose 125 mg). 2–11 years; 15 mg/kg twice |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Present in milk in low concentration, but appropriate to use. |